SAN FRANCISCO, April 10, 2017 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report entitled “Powering the Life Sciences Commercial Engine with Market Access Insights.” Based on results from a survey of 60 industry leaders working in market access, medical affairs, marketing and sales, the report examines the challenges with effective market access data integration between market access and commercial teams, and key opportunities to reengineer the business for the future.
According to this report, all survey respondents recognized the importance of a market access-driven commercial model, and the need to more effectively share data to gain any competitive advantage that a formulary change might offer. In fact, more than 40% of participants cite data integration and sharing as the biggest barrier to collaboration between managed markets and sales and marketing teams. Organizational silos and disparate technology solutions play a significant role in these challenges.
“It’s clear from the survey that the Life Sciences industry still needs solutions for effective pull-through by field sales for market access opportunities created by managed care teams” said Lance Scott, chief executive officer, Zephyr Health. “While pharmaceutical companies have a clear understanding of the power these insights can provide, in terms of commercial success, breaking down silos throughout the organization is essential to data integration of any kind. However, these efforts must be supplemented with technology that disseminates rich and predictive insights across the organization in order to stay ahead of competition.”
The “Powering the Life Sciences Commercial Engine with Market Access Insight” global survey examined the landscape for pharmaceutical companies seeking to bridge the insights gap between market access teams and other commercial functions. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers, and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for Zephyr Health: [email protected]


AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



